Purine Supplementation in Patients With AICA-Ribosiduria
PURICA : Purine Supplementation in Patients With AICA-Ribosiduria
Centre Hospitalier Universitaire de Saint Etienne
10 participants
Apr 24, 2025
INTERVENTIONAL
Conditions
Summary
AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.
Eligibility
Inclusion Criteria1
- Individual affected by AICA-ribosiduria due to ATIC deficiency
Exclusion Criteria1
- \- Individual already on a purine-rich diet theoretical contraindication to a purine-rich diet
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
diet to achieve a purine intake of 160mg/d
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06845501